Navidea Biopharmaceuticals, Inc. Press Releases

NAVB 
$1.28
*  
unch
unch
Get NAVB Alerts
*Delayed - data as of Aug. 27, 2014  -  Find a broker to begin trading NAVB now
Exchange: AMEX
Industry: Health Care
Community Rating:
View:    NAVB After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Navidea Announces Second Quarter 2014 Financial Results; Total Revenues Grow to $1.1 Million
8/6/2014 7:30:00 AM - Business Wire

Navidea Biopharmaceuticals to Announce Second Quarter 2014 Financial Results on August 6, 2014
7/29/2014 9:37:00 AM - Business Wire

Navidea Biopharmaceuticals Announces 2014 Annual Meeting Results
7/17/2014 3:44:00 PM - Business Wire

Navidea Joins Essex Woodland’s Rheumco to Develop Radiopharmaceuticals for Detection and Treatment of Arthritic Diseases
7/16/2014 7:30:00 AM - Business Wire

Navidea to Webcast Investor Briefing on Sentinel Lymph Node Biopsy in Head & Neck Cancers July 8, 2014
7/2/2014 5:06:00 PM - Business Wire

Navidea Biopharmaceuticals to Present at the 9th Annual JMP Securities Healthcare Conference
6/17/2014 4:30:00 PM - Business Wire

U.S. FDA Approves Navidea Biopharmaceuticals’ Lymphoseek® (technetium Tc 99m tilmanocept) Injection for Expanded Use in Head and Neck Cancer Sentinel Lymph Node Biopsy
6/13/2014 12:26:00 PM - Business Wire

Navidea Biopharmaceuticals’ Lymphoseek® (technetium Tc 99m tilmanocept) Injection Demonstrates Preferential Accumulation in Tumor-Positive Sentinel Lymph Nodes in Post-Hoc Analysis
6/11/2014 7:30:00 AM - Business Wire

Navidea Biopharmaceuticals Announces Positive Lymphoseek® (technetium Tc 99m tilmanocept) Injection Results on Injection Timing and Surgery Across Multiple Solid Tumor Types
6/10/2014 4:30:00 PM - Business Wire

Biotech Stocks Technical Data -- Research on Navidea Biopharma, Alkermes, Nanosphere, and Organovo Holdings
6/10/2014 8:00:00 AM - PR Newswire

Navidea Announces Data Demonstrating Potential of Manocept™ Platform to Diagnose Rheumatoid Arthritis and Kaposi’s Sarcoma
6/10/2014 8:00:00 AM - Business Wire